Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class.

It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals.

[1][2][3][4] It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor.

[5][6] Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed.

Squibb and Sons in the 1970s.